Cellosaurus HLE (CVCL_1281)

Cell line name HLE
Accession CVCL_1281
Resource Identification Initiative To cite this cell line use: HLE (RRID:CVCL_1281)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: JFCR45 cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Doubling time: 40 hours (PubMed=52570).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: TP53 p.Arg249Ser (PubMed=8389256).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Hepatocellular carcinoma (NCIt: C3099)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_JF92 (HLE-LUC)CVCL_X149 (HLE/2E1)
Originate from same individual CVCL_2947 ! HLF
Sex of cell Male
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10
D13S3178
D16S5399,11
D18S5115
D21S1131.2,32.2
D3S135815,17
D5S81811
D7S82011
D8S117912,14
FGA21,24
Penta D9
Penta E21
TH016,9
TPOX8
vWA16
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=52570; DOI=10.20772/cancersci1959.66.4_385
Doi I., Namba M., Sato J.
Establishment and some biological characteristics of human hepatoma cell lines.
Gann 66:385-392(1975)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)

PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x
Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M., Ohnishi Y., Xiao H.Y., Nagai Y., Takagi H.
Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells.
Jpn. J. Cancer Res. 82:1428-1435(1991)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=12679910; DOI=10.3748/wjg.v9.i4.683
Liu L.-X., Liu Z.-H., Jiang H.-C., Zhang W.-H., Qi S.-Y., Hu J., Wang X.-Q., Wu M.
Gene expression profiles of hepatoma cell line HLE.
World J. Gastroenterol. 9:683-687(2003)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections JCRB; JCRB0404
Cell line databases/resources CCLE; HLE_LIVER
CGH-DB; 9075-4
Cosmic-CLP; 907057
GDSC; 907057
LINCS_LDP; LCL-1939
TOKU-E; 3605
Ontologies BTO; BTO:0005987
Biological sample resources BioSample; SAMN03473204
Chemistry resources ChEMBL-Cells; CHEMBL3308108
ChEMBL-Targets; CHEMBL1075464
Gene expression databases GEO; GSM827170
GEO; GSM887084
GEO; GSM888154
GEO; GSM936757
GEO; GSM1374537
GEO; GSM1669884
Polymorphism and mutation databases Cosmic; 907057
Cosmic; 945156
Cosmic; 1518230
Cosmic; 2023859
Cosmic; 2162526